We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.46 | -1.50% | 95.81 | 97.83 | 97.11 | 97.63 | 1,180,808 | 01:00:00 |
From May 2019 to May 2024
By Pietro Lombardi
Novartis AG's Sandoz division is evaluating its options, including a potential appeal to the U.S. Supreme Court, after a U.S. court ruled against the company in a patent litigation related to the Sandoz biosimilar Erelzi.
The Swiss drugmaker said Wednesday that the U.S. Court of Appeals for the Federal District upheld a previous ruling declaring Amgen Inc.'s patents valid.
"Sandoz will continue its efforts to make Erelzi available to U.S. patients with autoimmune and inflammatory diseases," said Carol Lynch, president of Sandoz U.S. and head of North America. "Our company respects valid intellectual property, however Sandoz continues to believe the patents asserted by Amgen are not valid, and that it should not be able to use them to extend the drug's exclusivity."
Sandoz's biosimilar Erelzi was approved by the U.S. Food and Drug Administration in 2016 but the company hasn't been able to launch it in the U.S. due to the patent litigation with Amgen.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
July 01, 2020 12:45 ET (16:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
